Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07048496 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

Study acronym: BCG at Home
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Aug 5, 2026 → Feb 5, 2027
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Primary completion pushed from Aug 5, 2026 to Feb 5, 2027 Completion pushed from Sep 5, 2026 to Apr 5, 2027 · Eligibility criteria expanded, about 11 words Show 2 more changesShow less
    • Completion pushed from Sep 5, 2026 to Apr 5, 2027
    • Eligibility criteria expanded, about 11 words
  2. Lead sponsor: University of Pennsylvania to Abramson Cancer Center at Penn Medicine Collaborators expanded, about 4 wordsv3 Show 1 more changeShow less
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.
Trial Details
NCT Number NCT07048496
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Blue Cross Blue Shield
Conditions Bladder Cancer
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov